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Abstract: Allosteric drugs are usually more specific and have fewer side effects than orthosteric drugs targeting the same 
protein. Here, we overview the current knowledge on allosteric signal transmission from the network point of view, and 
show that most intra-protein conformational changes may be dynamically transmitted across protein-protein interaction 
and signaling networks of the cell. Allo-network drugs influence the pharmacological target protein indirectly using spe-
cific inter-protein network pathways. We show that allo-network drugs may have a higher efficiency to change the net-
works of human cells than those of other organisms, and can be designed to have specific effects on cells in a diseased 
state. Finally, we summarize possible methods to identify allo-network drug targets and sites, which may develop to a 
promising new area of systems-based drug design. 
Keywords: Allo-network drugs; allosteric drugs; interactome; protein-protein interaction networks; protein structure networks; 
signaling networks. 
1. INTRODUCTION 
Fast and affordable drug development is a requirement 
that contrasts with the current state of drug discovery. Drug 
development often fails because the development process 
does not always take into account the vast complexity of the 
cell and the robustness of its networks. In recent years, sys-
tems level and network analyses have become increasingly 
applied methods in drug design [1-14].  
In this review, we first give a network-focused overview 
of how allosteric changes propagate within proteins, and 
how this signal transduction process can be extended to pro-
tein complexes and larger segments of protein-protein inter-
action and signaling networks. Further, we describe the 
benefits and the limitations of network-based methods to 
analyze allosteric action. Then we introduce the concept of 
allo-network drugs [15], i.e. drugs acting indirectly, via the 
inter-protein propagation of changes in cellular networks. 
We show that allo-network drugs may have special benefits 
in human cells, and may be designed to have specific effects 
on cells of diseased organisms. The review is concluded by 
the suggestion of several methods to identify allo-network 
drug targets and their binding sites including determination 
of network centralities, network hierarchy, controllability, 
assessment of perturbation propagation in networks, the 
analysis of correlated motions, reverse engineering methods 
to reveal central and less frequently used pathways, analysis 
of evolutionary conservation, as well as of biological 
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disease-related systems data or system-level responses of the 
cell to drugs. We conclude that the development of allo-
network drugs appears as a promising new trend in drug de-
sign. 
2. THE PROPAGATION OF ALLOSTERIC EFFECTS 
AND PROTEIN STRUCTURE NETWORKS 
2.1. The Concept of Allostery 
Several questions of protein dynamics such as the 
mechanism of allosteric changes gained much attention in 
the last century [16-22] but have not been completely eluci-
dated yet. The molecular mechanisms of allostery have been 
typically discussed in terms of two classical models, the 
Monod-Wyman-Changeux (MWC) [23] and the Koshland-
Némethy-Filmer (KNF) [24] models. Although these models 
were originally developed for describing allostery in homo-
oligomers, their modernized versions also apply to mono-
meric proteins and other types of allosteric systems [25]. 
Both models assume that the protein can exist in two major 
conformations (e.g. tense and relaxed or active and inactive). 
According to the MWC model, equilibrium exists between 
the two conformations at all times, and the binding of the 
allosteric effector only modifies this equilibrium, causing a 
population shift [26]. In contrast, the KNF model assumes 
that the new conformation does not pre-exist before the bind-
ing of the effector but is instead induced by the binding 
event through a series of sequential steps. Experimental evi-
dence supports the MWC model in many cases, such that it 
has been argued that it can claim victory [27], even though it 
has been acknowledged that local ligand-dependent move-
ments may occur in agreement with the KNF mechanism. 
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Others have argued that the MWC and KNF scenarios are 
just extremes of a range of possible allosteric mechanisms 
[28]. 
A modern extension of the MWC mechanism stresses 
that most proteins do not exist in only two possible states but 
form a large ensemble of states, and the allosteric change 
represents a redistribution of population intensities within 
this ensemble, i.e. a population shift [29]. In addition, allos-
tery may occur without a conformational change [30,31], 
which led to the new concept of dynamically driven allostery 
[32] and the notion that all proteins may be capable of being 
allosterically regulated. A recent classification of allosteric 
mechanisms considers the extent of conformational change, 
and whether the allostery is driven by enthalpy, entropy, or 
both [33]. 
2.2. Communication Pathways and Intra-Protein Net-
works 
Regardless of the particular mechanism of allostery, it is 
recognized that information is in some way transmitted from 
the allosteric site to the substrate site, which implies the exis-
tence of communication pathways within the protein. There-
fore, considerable experimental and computational effort has 
been devoted to discovering these pathways. It should be 
noted, though, that allostery has also been conceptually un-
derstood in purely thermodynamic terms, as in the ensemble 
view of allostery [34], which does not require the existence 
of specific pathways for the propagation of allosteric infor-
mation. 
The notion of intra-protein communication pathways in-
spires a network view of proteins. In this view, the protein is 
represented as a graph where nodes are (usually) amino acid 
residues and edges are defined based on some relationship 
between residues [35-45]. Communication from one site to 
another may thus occur along the edges of the graph. 
As detailed in the following examples, there are many 
ways of defining networks within proteins. The procedure 
may start with a single structure, several structures (e.g. inac-
tive and active forms), or an ensemble of structures obtained 
from molecular dynamics (MD) simulations or other ap-
proaches. Edges (weighted or unweighted) may be defined 
based on a simple distance cutoff criterion, interaction 
strength or energy, the comparison of structures, or an analy-
sis of the ensemble. Experimental results are also used to 
define various networks within proteins. 
2.3. Properties of Protein Structure Networks 
The properties of protein structure networks (networks 
based on static structures) have been studied in detail [35-
45]. When the network is defined based on a distance cutoff, 
interaction cutoff or energy cutoff, it undergoes a percolation 
transition in a narrow range of the cutoff as the size of the 
largest connected component increases to eventually cover 
the whole protein [40,46]. The clustering coefficient tends to 
be homogeneous in the protein core, and characteristic path 
lengths of residues have been shown to correlate well with 
residue fluctuations [39]. Hubs tend to connect secondary 
structure elements, and have a preference for certain amino 
acids (mainly aromatic ones and arginine) [40]. 
It has been shown that residues with a high closeness in-
dex in the network tend to be functionally important, and are 
often at active sites [47,48]. Networks spanning protein-
protein interfaces have also been analyzed, with the general 
finding that hot spots at such interfaces tend to occur in clus-
ters and are highly central [49-52]. In addition, protein struc-
ture networks have been used in studies of protein folding 
and unfolding [53-56]. 
2.4. Methods to Identify Allosteric Pathways in Intra-
Protein Networks 
Once an intra-protein network has been defined, various 
techniques can be used to find allosteric communication 
pathways within the network. One common method is to 
search for shortest paths connecting the allosteric and sub-
strate sites [57-65]. This method identifies the residues most 
frequently occurring along these shortest paths. Another 
concept that is often embraced is to consider the protein as a 
set of modules (subgraphs with many connections within 
them but few connections between them). It has been shown 
that many proteins have a modular architecture, with mod-
ules corresponding to (often functionally distinct) subdo-
mains. Residues between modules tend to be conserved and 
more rigid, and are thought to be involved in allosteric 
communication [66-69]. Several studies have employed the 
concept of modules or a related notion [69-71]. 
2.5. Statistical Coupling Analysis 
In 1999, Lockless and Ranganathan [72] published an in-
fluential paper that introduced the idea of allosteric commu-
nication pathways, which inspired many experimental and 
computational studies. In this paper, the authors used statisti-
cal coupling analysis (SCA), a technique that uses a multiple 
sequence alignment to identify a coevolving set of residues 
in a protein family, to identify in the PDZ protein family a 
sparse network of residues representing what they called 
evolutionarily conserved pathways of energetic connectivity. 
Point mutations have been used to experimentally confirm 
the energetic coupling between the residues in the network. 
This method was then applied to reveal the communication 
pathways in a number of other proteins [73-77], and the pre-
dictions of the original paper have been supported by NMR 
measurements [78]. Although these studies showed the suc-
cess of the SCA method, comparison with thermodynamic 
coupling data from double mutant cycles showed that while 
SCA does find some of the physically close, coupled resi-
dues, it does not find all of them [79]. Indeed, an exhaustive 
study using double mutant cycles found that coupling is not a 
special property of the residues in the coevolving network 
originally identified for the PDZ family [80]. A more recent 
lattice model study also noted some apparent discrepancies 
between SCA and mutational studies [81]. In spite of these 
apparent limitations, SCA continues to be successfully used 
in various studies [82-85]. 
2.6. Networks from Experiments 
Although there are many computational techniques to de-
tect allosteric communication pathways, it is difficult to dis-
cover those directly using experimental methods. As men-
tioned, SCA results were validated by mutational studies. 
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Energetic coupling between residues can be reliably meas-
ured by double mutant cycles. However, a full energetic de-
scription of an allosteric pathway requires the examination of 
higher-order couplings, which can only be performed by 
triple, quadruple, etc. mutants. Clearly, the number of re-
quired constructs quickly grows prohibitively high. In an 
impressive study, 46 different mutants were used to reveal a 
highly cooperative, sharply delineated allosteric pathway in a 
voltage-gated potassium channel [86]. Energetic couplings 
were found to be highly anisotropic, not corresponding to a 
distance relationship, which suggests that there is an actual 
pathway of successive physical deformations. 
NMR based techniques have been used to discover allos-
teric communication pathways in a number of proteins, with 
remarkable results [87,88]. Of special interest is the discov-
ery of dynamic couplings and allosteric behavior in a non-
allosteric protein, eglin c [89]. It was demonstrated that en-
ergy transmission is unidirectional, i.e. perturbing the protein 
at one site may elicit a change at another site, but this proc-
ess does not always occur in the reverse direction. The net-
works of dynamical couplings were revealed in several dif-
ferent mutants of eglin c, and were found to be different. In 
one mutant that showed subtle conformational changes from 
the wild-type protein, the network of dynamical couplings 
was not physically contiguous. The propagation of allosteric 
signals was explained by a change in residue rotamer popu-
lations [89]. 
Recently, a highly powerful technique named “chemical 
shift covariance analysis” (CHESCA) was developed and 
validated by mutational studies [90,91]. The method pro-
vides a detailed picture of both the structurally and the dy-
namically mediated allosteric changes, quantitatively de-
scribing the relative contribution of each residue to binding 
and allostery. 
2.7. Multiple Pre-Existing Pathways 
The growing number of experimental and computational 
studies of allosteric communication pathways led to the con-
cept that there are multiple pathways, which pre-exist before 
the binding of the allosteric effector, much like all functional 
conformations pre-exist in the conformational ensemble be-
fore an effector is bound [92]. Major and minor pathways 
may exist as suggested by the different effect of mutations 
upon the allosteric signal transmission. An MD based com-
putational analysis of communication pathways in Met-
tRNA synthase, however, indicated that only fragments of 
pathways are present in the apo states of the protein, with the 
full pathway only appearing when both substrates are bound 
[59]. This indicates the dependence of various pathways on 
subtle structural changes. A given pathway may only pre-
exist in a scarcely populated subset of the native ensemble 
and thus may not be readily detected in MD simulations. 
2.8. Allosteric Communication Pathways from Static 
Structures 
A number of studies simply used a single structure or a 
small number of structures to define networks, and extract 
communication pathways. In myosin, this method was used 
to identify shortest paths between the ATP binding site and 
the lever arm, defining a communication pathway by con-
served residues along the paths [60]. Another study identi-
fied those conserved residues that had the largest contribu-
tion to maintaining short paths within the protein structure 
network; the results showed good agreement with experi-
mental findings for 7 protein families [57]. For proteins un-
dergoing a clear conformational change due to allostery, 
pairs of structures can be used to obtain an insight into the 
allosteric mechanism [93]. It was found that a communica-
tion pathway is best identified by combining the network of 
rigid substructures with the network of contact rearrange-
ments [94]. 
For a better description of information flow in the net-
work, some studies use an information theoretical approach, 
converting the protein structure network into a Markovian 
model of information propagation [71,95-97]. By defining 
soft clusters in the Markovian network and identifying hub 
and ‘messenger’ residues, two main communication path-
ways were discovered in the GroEL-GroES system [71]. In a 
later study, it was shown that the commute time between two 
residues (as calculated from the Markov propagation model) 
is proportional to the fluctuations in the distance between 
these residues (as calculated from an elastic network model), 
thereby bridging the gap between information theory and 
physics based models [98]. 
2.9. Communication Pathways from Elastic Network 
Models 
Elastic network models (ENMs) are various coarse-
grained models of proteins that are typically defined from a 
single protein structure based on a residue-residue distance 
criterion, and studied by normal mode analysis [99]. Such 
models have proven successful for describing functional 
motions (including allosteric motions) in proteins, especially 
when the protein consists of large, rigid regions connected 
by more flexible linker regions [28,100]. ENMs have been 
used in various ways to define communication pathways. In 
the “structural perturbation method”, the response of the 
network to a local structural perturbation is mapped out to 
define an allostery wiring diagram [101,102]. The similar 
“perturbation response scanning” method examines the dis-
placement of residues when a force is applied on a selected 
residue [103]. A recent “electro-elastic network model” at-
tempts to account for hydration, and is used to study the ef-
fect of solvation upon allosteric changes [104]. 
2.10. Allosteric Communication from an Ensemble of 
Structures 
Recognizing the fact that proteins are dynamic entities, 
many techniques have been developed to define communica-
tion pathways in proteins from ensembles of structures. Mo-
lecular dynamics simulation (MD) is the most common 
method to generate ensembles of protein conformations. 
Once an MD trajectory is generated, the edges of a residue 
network are defined based on various quantities obtained by 
analyzing the trajectory. Edges between residues may be 
defined based on the correlation of displacements of the at-
oms (usually the C atom) [59,61,64,105], the fluctuation of 
C-C distances [106,107], generalized correlations [63], 
interaction energy correlations [108,109], mutual informa-
tion between torsion angles [110], and discretized backbone 
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conformations of segments [65]. In several cases, this net-
work was further filtered or combined with distance based 
networks to ensure physical contact between correlated resi-
dues. The resulting network was then analyzed by the same 
methods as those used for static structures, i.e. finding short-
est paths, hubs, clusters, modules, etc. 
A different ensemble-based approach has been adopted 
by Hilser and colleagues [111,112]. Instead of generating an 
ensemble of actual conformations, a statistical mechanics 
approach is used. The COREX algorithm generates states 
with all possible combinations of locally unfolded or folded 
segments, and the energies of these states are estimated. In 
this approach, the energetic couplings between residues can 
be determined. Using energetic perturbations, the method 
reveals the cooperative network of the protein, and it can 
also determine the global allosteric response to mutations 
[113]. A remarkable conclusion arising from this approach is 
that cooperative coupling between sites does not require the 
existence of a specific energetic pathway. Instead, such cou-
pling can be explained by the hierarchy of energetically ex-
cited states in the native ensemble. The validity of the ap-
proach was experimentally confirmed by creating a new al-
losteric effect by increasing the probability of some locally 
unfolded states in adenylate kinase, without changing the 
native structure [114]. 
2.11. Energy Propagation in Proteins 
An allosteric effect can be regarded as a local energetic 
perturbation of a protein, which then propagates within the 
protein matrix to eventually reach the substrate site [115]. 
Several studies have been devoted to the investigation of 
energy transmission processes within proteins. The investi-
gation of vibrational energy flow on all-atom models [116] 
found that the flow is anisotropic and the protein can be ap-
proximated as a percolation cluster [117] with a fractal di-
mension ~2.5. Energy is transferred between vibrational 
modes via anharmonic coupling. Based on a similar normal 
mode analysis, frequency-resolved communication maps 
were constructed for myoglobin [118]. At low frequencies, 
modes are global, and some channels are observed that could 
transfer energy away from the heme group. The communica-
tion map resembles the contact map. At higher frequencies, 
however, the map is very frequency-dependent. It should be 
noted that energy transfer by these processes is typically 
much faster (on the picosecond time scale) than most allos-
teric processes, therefore the relevance of these energy flow 
channels to allostery is uncertain. 
Energy flow was also studied by elastic network models. 
Using an anharmonic model, it was shown that “discrete 
breathers”, localized vibrational modes easily form in pro-
teins at the stiffest regions, and are able to pump and store 
energy from neighboring sites. Thus, energy can ‘jump’ from 
site to site via this mechanism, often covering long distances 
[119,120]. In a Gaussian network model, the correlations 
between the energy fluctuations of residues were calculated, 
and were found to define an interaction pathway which was 
similar to the pathway defined by the co-evolving network of 
residues in the PDZ domain [121]. 
Energy flow within proteins was also investigated by a 
number of MD techniques. In the method of anisotropic 
thermal diffusion, a single amino acid is suddenly heated to 
300 K while the rest of the protein is at 10 K, and the diffu-
sion of heat within the protein is monitored [122-124]. In 
pump-probe MD, selected atoms are excited by oscillating 
forces, and the transmission of the oscillations to other parts 
of the protein is monitored [125]. Similar methods are based 
on measuring the times energy is transmitted from the site of 
perturbation to other residues [126,127], and the time corre-
lations of the energy flow between residues [128]. Although 
the perturbations used in these methods may be unphysically 
large, all these methods reveal the anisotropy and pathways 
of intra-protein energy transmission. Often, the communica-
tion pathways found by these methods are similar to those 
identified by other methods such as SCA. 
A method has been developed to quantitate the local en-
ergetic frustration in proteins [129]. ‘Frustratograms’, net-
works of minimally and highly frustrated residue pair inter-
actions, were calculated for a number of proteins, and it was 
shown that the regions that reconfigure during an allosteric 
conformational change tend to be enriched in patches of 
highly frustrated interactions [130]. This and similar findings 
have led to the idea that intra-protein communication may 
occur via a front of highly frustrated residues, and ligand 
binding may induce a flipping of residues within a ‘frustra-
tion tube’ [28]. 
Our current understanding indicates that allosteric 
changes may have two major molecular mechanisms. In al-
losteric proteins where signaling involves only a small num-
ber of amino acids, a switch-type conformational change is 
typical. When allosteric signaling involves a large number of 
amino acids signals usually propagate at multiple, seemingly 
fuzzy trajectories which tend to converge at inter-domain 
boundaries. While protein segments involved in switch-type 
allosteric changes may be more rigid, protein segments har-
boring multiple trajectories may be more flexible. Some pro-
teins may have a mixture of the above two mechanisms for 
the propagation of conformational changes. If the binding of 
an allosteric effector makes certain protein segments more 
rigid, the signal may propagate by a mechanism closer to the 
first, switch-type mechanism, resulting in an efficient, salta-
toric signal transduction. This can be conceptualized as the 
propagation of a ‘rigidity-front’ [1,45,131]. The ‘rigidiza-
tion’ of a protein segment may accelerate the propagation of 
the allosteric change within the segment and induce similar 
changes in the neighboring segment. Rigidity front propaga-
tion may use sequential energy transfers [22,120], and thus 
may significantly increase the speed of the allosteric change 
[1,45]. The rigidity front propagation model combines ele-
ments of ‘rigidity propagation’ [132-134] with the ‘frustra-
tion front’ concept of Zhuravlev and Papoian [28], and it is 
in agreement with the recent proposal of Dixit and Verk-
hivker [135] suggesting an interaction network of minimally 
frustrated (rigid) anchor sites and locally frustrated (flexible) 
proximal recognition sites to play a key role in allosteric 
signaling. 
2.12. Finding Allosteric Sites by Network-Based Methods 
Discovering new allosteric sites in proteins opens up a 
new way of designing more specific drugs [87]. Thus, it is of 
interest to develop methods that can identify allosteric hot 
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spots on protein surfaces [136,137]. Communication path-
ways predicted by SCA were used to find allosteric hot spots 
in dihydrofolate reductase (DHFR), and a chimeric protein 
was created by inserting a light-sensitive domain into DHFR 
at a predicted allosteric site, thereby obtaining an enzyme 
that can be regulated by light [84]. As a continuation of this 
experiment, it was shown by the same method that the set of 
all allosteric hot spots is almost identical to the set of surface 
sites connected to network defined by SCA, and a similar 
conclusion was made about a PDZ domain [85]. These find-
ings also give an insight into how new sites for allosteric 
regulation may naturally evolve. 
2.13. Limitations of Protein Structure Networks for the 
Study of Allosteric Communication 
Studying allosteric communication by network analysis 
of protein structure graphs is a powerful approach based on 
an intuitive concept, and has yielded plausible and occasion-
ally, experimentally validated results. However, it is not 
without limitations. 
As we have seen, there are many ways of defining intra-
protein networks, and not all methods give the same result. 
An MD based study using restraints from NMR experiments 
showed that the network obtained by mapping structural 
changes differs from that obtained from dynamical changes, 
and both are different from the co-evolving network obtained 
by SCA (although the overlap between the SCA and the dy-
namical network is larger) [138]. The network obtained by 
mapping torsion angle correlations is also different from that 
obtained from position correlations [110]. The hubs in a 
network obtained from Lennard-Jones energies tend to be 
located in the protein core, while those defined in the net-
work based on full interaction energies tend to be at the sur-
face [46]. 
A network constructed from a single, static structure can-
not account for conformational changes. Communication 
pathways may not always pre-exist or may only be present in 
a scarcely populated subset of the native ensemble, thus eas-
ily evading detection even via ensemble-based methods. It 
was shown that the full communication path only gets as-
sembled in Met-tRNA synthase when both substrates are 
bound [59]. Methods based on MD simulations yield net-
works reflecting different time scales of events, from the 
picosecond [126] to the tens of nanoseconds [110] range. In 
an MD study based on torsion angles, correlations between 
distant side chains were seen without a correlated chain of 
residues between them [110]. In this case, the correlation is 
probably mediated by events on a faster time scale that is not 
captured by the method. 
Communication pathways built from residue-residue con-
tact-based protein structure networks often lack a true physi-
cal basis (with the exception of elastic networks). Different 
types of perturbations may activate different communication 
pathways within a protein; e.g. a targeted, strong perturba-
tion elicited by ligand binding may get propagated differ-
ently than thermal noise from the solvent [58]. Protein struc-
ture networks often do not take into account the differences 
in these perturbation types. 
Most network-based methods to reveal communication 
pathways do not take side chain rotations into account, even 
though these have been shown to be involved in allosteric 
communication via rotamer population shifts 
[89,110,138,139]. Side-chain rotations generate their own 
network, which is impossible to map out from a static struc-
ture [140]. Many methods only use C coordinates, although 
it has been shown that side chains should be included for 
best results [70]. 
All intra-protein network construction methods consider 
residues as nodes in the network. Although this is an obvious 
choice, residues have widely different sizes and physico-
chemical properties, which may bias the results of the analy-
sis. For example, hubs are very often aromatic residues [57], 
which is at least in part due to their bulkiness [40]. In fact, 
residue types have different network properties due to their 
physico-chemical differences [141,142]. It was shown that a 
graph with chemical groups (groups of chemically similar 
atoms) as nodes is more suitable for the analysis of MD 
simulations than residue-based graphs [143]. 
Allostery itself may occur by a number of mechanisms, 
involving large or small or no conformational change, driven 
by enthalpy (structure), entropy (dynamics) or both [33], and 
the time scale of the allosteric change may also vary over a 
wide range. The protein may be highly modular or may con-
sist of only a single, rigid domain. Ideally, the choice of 
method to describe communication pathways should depend 
on the particular protein, as well as the type and time scale of 
the allosteric change under study. 
Even though network construction methods will always 
yield some communication network, allosteric ‘information 
transmission’ may in some cases not involve any particular 
pathway at all, as suggested by the ensemble view of allos-
tery [144]. This may typically be the case for proteins where 
disordered regions or domains optimize allosteric coupling 
[45,144], or where significant segments of the protein struc-
ture are extremely rigid [1,45]. Network-based methods to 
reveal allosteric pathways may have difficulties with han-
dling significant disorder (i.e. extreme flexibility, plasticity) 
or extreme rigidity. 
Finally, intra-protein networks usually do not include 
solvent molecules, even though they may be part of the al-
losteric pathway. It has been shown that water molecules at 
the interface between the subunits of hemoglobin carry a 
large part of the energy and are probably involved in allos-
teric communication [145]. 
Future research will probably yield more advanced meth-
ods that will surmount some of the weaknesses of existing 
methods. Despite the limitations, the findings of many net-
work-based analyses of allostery have been supported by 
experiments, and the network view of proteins offers a useful 
framework for the discussion of allosteric processes. 
3. PROPAGATION OF SIGNALS IN CELLULAR 
NETWORKS 
The propagation of allosteric signals is not limited to sin-
gle protein chains. The classical models of allostery describe 
allosteric effects in oligomeric proteins [23,24]. Network 
models of allosteric signal propagation have been applied to 
multimeric protein complexes [49-52]. Many of the exam-
ples of the preceding sections were also protein complexes. 
Allo-Network Drugs Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 1    69 
Cellular function can be described in terms of cellular 
networks such as protein-protein interaction networks, signal 
transduction networks, gene transcription networks, meta-
bolic networks, etc. [1,146,147]. Evolution has optimized the 
cellular machinery to rapidly respond to changing conditions 
by the use of modular functional organization and large mul-
timolecular assemblies. The binding of an allosteric effector 
to one protein may induce conformational or dynamic 
changes in adjacent proteins. The propagation of conforma-
tional changes is usually anisotropic and traverses across a 
pathway, thereby facilitating signal transduction over large 
distances (hundreds or thousands of angstroms). Thus, bind-
ing to a protein may elicit a limited, specific, and distant 
functional change in the network [15,33,115,148].  
A prime example of such functioning is the gigantic Me-
diator complex, which relays signals from specific DNA 
regulatory elements to initiate gene-specific transcription 
hundreds of angstroms away [149,150]. However, long-
range signaling does not necessarily require a giant complex, 
since the signal can also propagate in a stepwise manner, 
where only two nodes are involved in each signal transmis-
sion step. As an example of specific propagation of long-
range changes, Maslov and Ispolatov [151] used the law of 
mass action to calculate the effect of a two-fold increase in 
the expression of a single protein on the free concentration of 
other proteins in the yeast interactome. Despite of an expo-
nential decay of changes, there were a few highly selective 
pathways where concentration changes propagated to a 
larger distance [151]. The perturbation dynamics of signaling 
networks was extensively analyzed including ~10,000 phos-
phorylation events in an experimental study of yeast cells 
[152]. The size of the human interactome has been estimated 
to have 650,000 interactions [153]. Though several datasets 
have been published in the last decade [154-157], we are still 
a long way from deciphering the full complexity of the hu-
man interactome. Human signaling networks extend this 
complexity by the inclusion of directed and conditional in-
teractions, as well as microRNAs [1]. 
The number of possible regulatory combinations for a 
given gene increases dramatically with an increase in input 
complexity and network size. For example, with 100 genes 
and 3 inputs per gene, there are about a million input combi-
nations for each gene in the network, resulting in 10
600
 dif-
ferent network wiring diagrams [158]. Systems-level mo-
lecular networks have a 100-fold larger size. Estimates of the 
number of possible states of the yeast interactome range 
from 10
7,200
 to 10
79,000,000,000
 [159], which are all unimagina-
bly high numbers. The number of possible states of the hu-
man interactome, which is an order of magnitude larger, 
must be even higher. At this level of system complexity, 
current descriptions of network dynamics contain several 
simplifications, e.g. they neglect node-specific delays, dif-
ferences in individual dissipation patterns, effects of water, 
or molecular crowding. Most importantly, most current net-
work-level cellular signal transduction models do not take 
into account the highly anisotropic nature of the perturbation 
propagation inside protein structures [115]. Construction of 
atomic-level resolution protein-protein interaction and sig-
naling networks, with interacting 3D protein structures 
bound or docked at their experimentally shown or predicted 
binding sites, will be a major step towards high-resolution 
signal transduction models to understand long-range allos-
teric action. This step will add a new dimension of informa-
tion especially to protein-protein interaction networks, which 
at present mostly contain probability-type interactions lack-
ing structural and signal propagation details. A few protein-
protein interaction networks containing 3D protein structures 
have already been assembled [160-163], providing initial 
steps towards this goal. 
4. ALLO-NETWORK DRUGS: EXTENSION OF THE 
CONCEPT OF ALLOSTERIC DRUGS TO CELLU-
LAR NETWORKS 
Traditional, orthosteric drugs bind to active sites of en-
zymes. However, their selectivity is hard to ensure as pro-
teins acting on the same substrates (e.g. protein kinases 
which all use ATP) have similar active sites. To circumvent 
this problem, a number of allosteric drugs have been devel-
oped, mainly for seven transmembrane receptors, GPCRs 
[11,14,164-167] (see also other papers of this issue). Be-
cause allosteric drugs bind to sites different than the active 
site, they can be more specific, and thus usually have fewer 
side effects. Furthermore, allosteric drugs allow fine modula-
tion of function instead of the inhibition of the protein 
achieved by most orthosteric drugs. 
The combination of the concepts that intra-protein allos-
teric communication can be described via protein structure 
networks and that cellular function can be understood in 
terms of protein-protein interaction and signaling networks 
inspired a novel suggestion for drug target discovery: allo-
network drugs (Fig. (1), [15]). In this concept, instead of 
targeting a malfunctioning protein directly, a different pro-
tein in the cellular network neighborhood is targeted by the 
allo-network drug. The concept urges that drug discovery 
should harness the long-distance allosteric signal transduc-
tion pathways created by evolution to extend the scope of 
drug discovery targets. In allo-network drug action, the bind-
ing of the drug triggers a pathway of conformational (or dy-
namic) changes over a segment of the protein-protein inter-
action or signaling network, finally reaching a target protein, 
where it may then, for example, enhance or inhibit another 
pathway of propagating conformational changes. Because 
pathways evolved by nature are limited and specific, allo-
network drugs have the potential to be highly selective and 
disease-specific. This approach may dramatically increase 
the number of target proteins that can be considered as drug 
targets. 
Earlier works already pointed towards an allo-network 
type drug action, like the suggestion of inter-protein propa-
gation of allosteric effects [10,168] and the possible use of 
such an effect in drug design [7]. In fact, drugs that can be 
considered allo-network drugs already exist. Combination 
therapies and multi-target drugs combine multiple effects, 
often at places distant from the malfunctioning protein in the 
cellular network [2]. Examples from cancer drugs include B-
RAF and MEK combination therapy [169,170] and rapamy-
cin/FKBP12, an inhibitor of the mTORC1 complex 
[171,172]. Moreover, drug-target network studies revealed 
that in more than half of the established 922 drug-disease 
pairs, drugs do not target the actual disease-associated pro-
teins, but bind to their 3
rd
 or 4
th
 neighbors. However, the 
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Fig. (1). Allo-network drugs. The top part of the figure illustrates the protein structures of the allo-network drug target containing the pri-
mary binding site (green circle), a ‘transmission’ protein, and the final target. The bottom part of figure illustrates the positions of the same 3 
proteins in the human protein-protein interaction or signaling network. The red ellipse illustrates the ‘action radius’, i.e. the network perturba-
tion induced by the primary target. In the top part, signal propagation (illustrated by the light green arrows) extends beyond the original drug 
binding protein and affects two neighboring proteins in the network via specific interactions. The pharmacologically active final target is 
marked by a red asterisk. Orange arrows illustrate an intracellular pathway of propagating conformational changes, which is disease-specific 
in case of successful allo-network drugs. Allo-network drugs allow indirect and specific targeting of key proteins by a primary attack on a 
‘silent’ protein which is not involved in major cellular pathways. Targeting ‘silent’, ‘by-stander’ proteins, which specifically influence phar-
macological targets, not only expands the current list of drug targets, but also causes much less side-effects and toxicity. (The color version of 
the figure is available in the electronic copy of the article). 
 
distance between drug targets and disease-associated pro-
teins was regarded as a sign of palliative drug action [3,13], 
and the expansion of the concept of allosteric drug action to 
the interactome level has been formulated only recently [15].  
Thinking in network terms, the action of drugs can be 
perceived as a network perturbation. The drug-induced at-
tack either destroys the network of infectious or cancer cells, 
or shifts the pathophysiological network status back to nor-
mal [115,173-175]. Perturbation mediators in anti-infectious 
or anti-cancer therapies are often at cross-roads of cellular 
pathways. On the contrary, in other diseases such as diabetes 
or neurodegenerative diseases, efficient drug targets are not 
directly involved in major cellular pathways but indirectly 
influence them in a highly efficient manner [1]. Thus, the 
indirect but highly directed action of allo-network drugs can 
achieve specific, limited changes at the systems level, with 
fewer side-effects and lower toxicity than those of conven-
tional drugs [15]. In agreement with this assumption, drugs 
with targets less than 3 steps (or more than 4 steps) from a 
disease-associated protein were suggested to have more side-
effects and to fail more often [176]. However, rational drug 
design proceeded in the opposite direction, identifying drug 
targets closer to disease-associated proteins than earlier [3]. 
The recently observed reversal of this trend may be more 
productive. Allo-network drugs point exactly to this direc-
tion. 
5. ALLO-NETWORK DRUGS AS SPECIFIC EFFEC-
TORS OF DISEASE-AFFECTED HUMAN CELLS 
Human cells seem to have developed a larger complexity 
of their networks than other organisms. This is especially 
true for signaling networks, where major signaling pathways 
have all possible crosstalks in human cells, while the same is 
not at all true in C. elegans or in Drosophila [177]. The 
complexity of regulation also increased through additional 
binding factors, as, for example, apparent in the structure of 
the transcriptional Mediator mega-complex [149,178]. 
Not only the static network structure but network dynam-
ics also increased in human cells. The variability of human 
protein-protein interactions is much larger than that seen in 
other interactomes. Besides single-nucleotide polymor-
phisms, alternative splicing, addition of N- or C-terminal 
tags, partial proteolysis and other post-translational modifi-
cations (such as phosphorylation), as well as changes in pro-
tein expression patterns may dramatically re-configure pro-
tein complexes [179]. Moreover, the human interactome 
seems to have a higher proportion of 'sticky' proteins leading 
to more promiscuous interactions than the E. coli or S. cere-
visiae interactomes [180]. As an additional factor of network 
dynamics, the human interactome is enriched with disor-
dered proteins, causing dynamically fluctuating, ‘fuzzy’ in-
teraction patterns [45,181].  
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The increased inter-pathway signaling, as well as the 
coupled large assemblies, all extend the propagation pathway 
repertoire of inter-molecular allosteric changes. Complex 
organization is helped by increased modularity, but increased 
variability and disordered proteins help to cross module 
boundaries and amplify intra- and inter-protein allosteric 
relays [148]. Thus, allo-network drug-like action occurs 
most where it is needed most: in human cells.  
Promising allo-network drugs should interfere with dis-
ease-specific pathways [1,15]. Targeting disease-induced 
dynamical changes in molecular networks may be focused 
on transient interactions specific to disease. Thus, allo-
network drugs may also provide a novel solution to uncom-
petitive, ‘interfacial’ drug action [173,182,183]. 
Finally, current drugs usually inhibit protein-protein in-
teractions [184]. Allo-network drugs may also trap a protein 
in its inactive state [87,185]. This way, the inter-molecular, 
long-range conformational change is prevented by the allo-
network drug. However, importantly, besides inhibition, 
allo-network drugs may stabilize, restore and/or activate a 
protein, its function, or one (or more) of its interactions 
[186]. 
6. POSSIBLE METHODS TO IDENTIFY ALLO-
NETWORK DRUG TARGETS 
As it is conceivable from Fig. (1), at the molecular net-
work level, allo-network drug design needs to solve three 
closely related problems. 1.) An appropriate pharmacological 
target protein playing a crucial role in shifting the disease 
state of the cell back to normal should be found. 2.) An ap-
propriate allo-network drug target protein should be found 
which is in the network neighborhood of the pharmacologi-
cal target protein but plays no major role in cellular proc-
esses and therefore its direct manipulation has no major side-
effects. 3.) A communication channel should exist between 
the allo-network target of point 2 and the pharmacological 
target of point 1, i.e. the changes of the allo-network target 
should selectively propagate towards the pharmacological 
target in the atomic-resolution network structure.  
Since the above points 2 and 3 are related and set rather 
stringent requirements for the allo-network drug target, 
search procedures can be greatly facilitated by increasing the 
resolution of data on cellular networks (the interactome 
and/or the signaling network) to atomic or amino acid level. 
To obtain a map of a protein complex at atomic resolution, 
docking of 3D protein structures and the consequent connec-
tion of their protein structure networks are needed. A few 
protein-protein interaction networks containing 3D protein 
structures have already been assembled [160-163], providing 
initial steps towards this goal. These efforts may be extended 
by mapping the protein structures into low-resolution EM 
density maps [187]. Thus, allo-network drug targeting re-
quires the integration of our knowledge on protein structures, 
molecular networks, and their dynamics, focusing particu-
larly on disease-induced changes. The identification of 
promising drug targets requires a deep understanding of how 
the cellular networks (interactomes and signaling networks) 
work, along with detailed structural knowledge of the pro-
teins and complexes involved. To map the cellular networks 
at the atomic resolution level, experimental structural and 
functional data need to be combined with modeling tools to 
predict which proteins interact and how [188]. Construction 
of these atomic level cellular networks should also take into 
account that proteins in different conformations may interact 
with different partners and different drug molecules; there-
fore, dynamic protein-protein interaction [161] and signaling 
networks, as well as conformation-dependent drug-target 
networks [189] have to be used. 
We list a few possible methods to define allo-network 
drug target sites and allo-network pathways to the pharma-
cological targets in cellular networks at atomic level resolu-
tion (Fig. (2)). 
• Central residues play a key role in the transmission of 
allosteric changes [65,71,95,97,101,102,127,135,190-
193]. We may use a number of centrality measures [194], 
including perturbation-based or game-theoretical as-
sumptions [115,195], to find the level of importance of 
proteins and pathways in interactomes and signaling net-
works, and important amino acids in their extensions to 
atomic level resolution [69]. 
• At both the molecular network level and its extension to 
atomic level resolution, we may extract network hierar-
chy [69,196-201] to assess the importance of various 
nodes (proteins and/or amino acids). 
• We may find nodes or edges controlling the network by 
the application of recently published methods [201-207]. 
• Network-based analysis of perturbation propagation is a 
fruitful method to identify intra-protein allosteric path-
ways [21,44,45,59-61,71,93,97,102,111,127,208]. A suc-
cessful candidate for the inter-protein allosteric pathways 
involved in allo-network drug action disturbs network 
perturbations specific to a disease state of the cell at a site 
distant from the original drug-binding site. Perturbation 
analysis [115,195] applied to the atomic-level-resolution 
interactome in combination with disease-specific protein 
expression patterns may help the identification of such 
allo-network drug targets.  
• A general strategy for the identification of allosteric sites 
may involve finding large correlated motions between 
binding sites. This can reveal which residue-residue cor-
related motions change upon ligand binding, and thus can 
suggest new allosteric sites [209] even in integrated net-
works of protein mega-complexes. 
• Reverse engineering methods [158] allow us to discrimi-
nate between ‘high-intensity’ and ‘low-intensity’ com-
munication pathways both in molecular and atomic level 
networks, and thus may provide a larger safety margin 
for allo-network drugs. 
• Combination of evolutionary conservation data has 
proven to be an efficient predictor of intra-protein signal-
ing pathways [60,85,210-212]. Similar approaches may 
be extended to protein neighborhoods helping to find 
starting sites for allo-network drug action. 
• Disease-associated single-nucleotide polymorphisms 
(SNPs; [213]) and/or mutations [214] may often be part 
of the propagation pathways of allosteric effects. In-
frame mutations are enriched in interaction interfaces 
[214], and provide an interesting dataset that could be
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Fig. (2). Methods to find allo-network drugs. All middle segments and notations of the figure are the same as those explained in the legend 
of Fig. (1). (Top part: protein structures; green circle: allo-network drug binding site; light green arrows: signal propagation; red asterisk: 
pharmacologically active target; orange arrows: disease-specific pathway; bottom part: protein-protein interaction or signaling networks; red 
ellipse: ‘action radius’.) Boxes highlight the various network- and system-based methods helping the identification of allo-network drugs. 
(The color version of the figure is available in the electronic copy of the article). 
 
used to predict the existence of allo-network drug bind-
ing sites. 
 We also give a few additional hints and considerations 
for successful allo-network drug finding. 
• Databases of allosteric binding sites 
(http://mdl.shsmu.edu.cn/ASD [215]) help the identifica-
tion of possible sites of allo-network drug action. How-
ever, allo-network drugs may also bind to sites not used 
by natural ligands, and inter-molecular allosteric effects 
may use other sites beyond those involved in intra-
molecular allosterism. 
• Drugs may fail when the cell bypasses drug action via a 
parallel pathway. Therefore, it is important to obtain a 
complete view of the network and to identify possible al-
ternative pathways [216]. 
• Because allo-network drugs have systems-level effects, 
cell-based assays can be used to find such compounds, 
similar to classical allosteric drugs. A number of experi-
mental methods can be used to find and analyze cellular 
system-level responses. This may involve extensive 
pathway profiling and high-throughput RNAi screening 
[217]. 
Despite the considerable challenges, detailed structural 
and functional knowledge and understanding of the path-
ways and information flow in the cellular networks at atomic 
level resolution will help to circumvent the long trial-and-
error process that was followed by evolution to develop allo-
network action. 
CONCLUSION AND PERSPECTIVES 
We predict that allo-network drug related systems-level 
and network analysis methods will develop to 'rational allo-
network drug design' protocols in the coming years, and 
hope that these efforts will result in novel drugs with greater 
selectivity and effectiveness. Allo-network drugs may in-
volve drug targets that are not related at all to usual drug 
target families.  
However, the development of rational allo-network drug 
design protocols requires 1.) a much more detailed under-
standing of cellular network structure and dynamics at the 
atomic resolution level including forward and backward 
loops; 2.) understanding allosteric signal propagation in net-
works and finding the key points where this dynamics can be 
influenced in an indirect but efficient and selective manner 
from a larger distance [31]; 3.) incorporation of disease-
specific systems-level data and data on dynamics and net-
work specificities [216].  
Despite the considerable challenges, the rapidity of the 
increase in systems-level data on healthy and diseased cells 
and the remarkable progress of network analysis methodol-
ogy in the last few years gives us strong hope that the ra-
tional development of allo-network drugs will be a widely 
pursued option of the drug industry in a few years. 
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